Corbus Pharmaceuticals Holding (CRBP)

Sep 25, 2026

Corbus Pharmaceuticals Holdings, Inc. (CRBP) is gaining attention within the cannabis stocks sector following its recent report of positive topline data from the Canyon study for its oral CB-one receptor inverse agonist in obesity. This development highlights the company's potential to extend cannabinoid-pathway drug development. The article emphasizes that sustained market interest will depend on CRBP's consistent operational execution, customer response, and financial results in the upcoming reporting cycles, rather than just the initial announcement.

Sep 16, 2026

Corbus Pharmaceuticals insider Ben Yong sold 2,000 shares of the company's stock at $7.84 per share on September 14, 2026. This transaction reduced his holdings by approximately 17.6%, leaving him with 9,383 shares. The sale was disclosed via a Form 4 filing with the SEC, indicating an open-market or private sale.

Sep 15, 2026

Corbus Pharmaceuticals announced positive topline results from its CANYON-1 Phase 1b trial for CRB-913, an oral non-incretin obesity treatment. The drug showed significant weight loss across all doses with a favorable safety profile, including fewer gastrointestinal adverse events and minimal psychiatric side effects compared to previous drugs and existing GLP-1 therapies. The company plans to engage with the FDA for a Phase 2 trial and explore combination therapies.

Sep 14, 2026

Corbus Pharmaceuticals (CRBP) stock is gaining attention due to an upcoming webcast presenting topline Phase 1b CANYON-1 data for its obesity drug candidate, CRB-913. Despite recent profit-taking and a quarterly net loss, the company maintains strong liquidity, making the webcast a critical volatility event for traders. The appointment of a new CMO with inducement stock options further signals leadership's commitment to long-term value in oncology and obesity pipelines.